Compare · NVO vs SHPH
NVO vs SHPH
Side-by-side comparison of Novo Nordisk A/S (NVO) and Shuttle Pharmaceuticals Holdings Inc. (SHPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SHPH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 60975.2x SHPH ($3.5M).
- NVO has been more active in the news (9 items in the past 4 weeks vs 5 for SHPH).
- NVO has more recent analyst coverage (25 ratings vs 0 for SHPH).
- Company
- Novo Nordisk A/S
- Shuttle Pharmaceuticals Holdings Inc.
- Price
- -
- -
- Market cap
- $215.46B
- $3.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 9
- 5
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest SHPH
- SEC Form NT 10-Q filed by Shuttle Pharmaceuticals Holdings Inc.
- Amendment: Shuttle Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
- SEC Form DEFA14A filed by Shuttle Pharmaceuticals Holdings Inc.
- SEC Form DEF 14A filed by Shuttle Pharmaceuticals Holdings Inc.
- SEC Form PRE 14A filed by Shuttle Pharmaceuticals Holdings Inc.
- Large owner Hrt Financial Lp sold $372,704 worth of shares (83,149 units at $4.48), closing all direct ownership in the company (SEC Form 4)
- Large owner Hrt Financial Lp bought $30,212 worth of shares (8,997 units at $3.36), increasing direct ownership by 17% to 61,271 units (SEC Form 4)
- New insider Hrt Financial Lp claimed ownership of 60,540 shares (SEC Form 3)
- Large owner Hrt Financial Lp sold $100,461 worth of shares (29,111 units at $3.45), decreasing direct ownership by 36% to 52,274 units (SEC Form 4)
- Large owner Hrt Financial Lp bought $27,793 worth of shares (7,851 units at $3.54) and sold $31,667 worth of shares (9,022 units at $3.51), decreasing direct ownership by 1% to 81,385 units (SEC Form 4)